13th World Congress on Alternatives and Animal Use in the Life Sciences

📍 Rio de Janeiro, Brazil | 🗓 Aug 31-Sep 4

At this year’s conference SenzaGen and Unilever co-chair a scientific symposium, where Dr Andy Forreryd will present how GARD^® can be applied to derive a Point-of-Departure (PoD) for quantitative skin sensitization assessment.

Session #79

Using NAMs to derive PoDs for NGRA of skin sensitizers: Towards regulatory implementation

Time: 9:30-11:00 | Tuesday, September 2

Venue: Plenary Room

Together with speakers from Unilever, Research Institute for Fragrance Materials (RIFM), and Inotiv, this joint symposium will cover methodological innovations in New Approach Methodologies (NAMs), industry case studies on deriving Points of Departure (PoDs) for fragrances, and the challenges and opportunities for regulatory acceptance.

💻 Incorporating expert knowledge in the Skin Allergy Risk Assessment (SARA) Model: an integrated approach to testing and assessment (IATA) demonstrated in case studies.

Renato Ivan de Ávila, PhD @Unilever

💻 The GARD^®skin Dose-Response model to derive a PoD for quantitative skin sensitization assessment.

Andy Forreryd, PhD @SenzaGen

💻 Predicting PoD and potency categories using New Approach Methods: Practical experience from the fragrance industry.

Isabella Schember, PhD @Research Institute for Fragrance Materials (RIFM)

💻 Integrating NAMs for quantitative skin sensitization potency assessment into regulatory frameworks: experience from the work in OECD TG 497

Emily Reinke, PhD, D.A.B.T @Inotiv

Poster #167

GARD^®skin for Medical Devices: Pre-validation results for implementation in ISO 10993-10

The pre-validation study of GARD^®skin Medical Device confirms the method is functional, reproducible and sufficiently accurate to proceed to the validation study phase, as defined by the ISO TS11796.